FREE DOWNLOAD: Lay Summary Whitepaper
This complimentary lay summary whitepaper will explain:
- the ins and outs of lay summary writing,
- the importance of starting a pilot program,
- a checklist for lay reviewers, and
- strategic advice for becoming more transparent.
Click on the image for the full whitepaper.
This whitepaper was authored by Manager of Disclosures Services Kasim McLain, Senior Transparency Lead and Medical Writer Jennifer Pilgrim, and Associate Manager of Corporate Quality Jessica Alamdari.
Suggested For You
perspectives
September 3rd, 2026
From Signal to System: FDA Approval Does Not Mean Treatment Can Begin the Next Morning
perspectives
August 27th, 2026
Risk-Based Data Management: Moving Beyond Traditional Data Cleaning
perspectives
August 17th, 2026
From Signal to System: The Evidence Questions Psychedelic Therapies Must Answer
perspectives
August 11th, 2026
The Race to Faster Drug Development: A Quicker On-Ramp Doesn’t Help If You’re Headed the Wrong Way
perspectives
August 7th, 2026
UK Clinical Trial Transparency Changes for Phase I Studies: What Sponsors Need to Know
perspectives
July 31st, 2026
FDA Orphan Drug Designation Requirements: Key Mistakes to Avoid
perspectives
July 29th, 2026
From Signal to System: The Next Challenges for Psychedelic Therapies
perspectives
July 24th, 2026
FDA’s Latest Psychedelic Guidance: Key Changes and Implications for Sponsors
perspectives
July 7th, 2026
Don’t Veer for Deer: Why Drug Development Needs Steady Steering in the Age of AI and Real-Time Data
perspectives
July 6th, 2026
How REMS Defines the Patient Journey in Psychedelic Therapies
perspectives
June 30th, 2026
The Future of Biostatistics: Insights from Presenters at PSI 2026
perspectives
June 11th, 2026
AI in Regulatory Strategy: Practical Uses for Submission Readiness